Antithrombin is a serine protease inhibitor (serpin) that inhibits mainly thrombin (factor IIa) and factor Xa, but also factors VIIa, IXa, XIa, XIIa, kallikrein, and plasmin. Pharmacologically, heparin binds to antithrombin, exposing antithrombin's reactive site and accelerating antithrombin's activity approximately 1000-fold. Physiologically, heparan sulfate naturally lines endothelial cell surfaces, locally enhancing antithrombin's activity.Hereditary antithrombin deficiency is a hypercoagulable state with a 5-to-50-fold increased risk for venous thromboembolism (VTE). 1 Antithrombin deficiency has autosomal dominant inheritance, occurring in 0.02%-0.17% of the general population and in 1%-5% of patients with VTE. [1][2][3][4] The first VTE usually occurs between the ages of 10-50 years, which is similar to protein C and protein S